RhoVac AB
RhoVac’s mission is to develop, and license after PIIb, therapy that specifically targets metastatic potential cells, preventing cancer recurrence and progression, after primary tumour therapy.
Scheeletorget 1, 223 81 Lund, Sweden Lund, Scania 22381, Sweden
Phone: 46708604738
Email: ama@rhovac.com